Conference Call to be Held at 8:30 a.m. ET
Anticipates full year 2025 total revenue of $292 million, exceeding the guidance range of $285-$290 million and reflecting growth of 44% compared to the prior year ...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...
Corcept shares crash as the FDA rejects its application for relacorilant. But is it worth buying CORT stock on the pullback?
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...
Total product revenue increased 40% YoY to $74 million Recorlev® revenue grew 109% YoY to $37 million Updating full-year 2025 total revenue guidance to $285-$290 million; previously $280-$290...
Conference Call to be Held at 8:30 a.m. ET
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...
Recorlev now holds four Orange Book-listed patents to 2040